Geneva named European Capital of Brain Health 2026
Life sciences
6 July 2026
Geneva was named European Capital of Brain Health 2026 by the European Academy of Neurology, in recognition of its ability to bring together cutting-edge research, innovation and leading institutions dedicated to brain health.
Geneva has been named European Capital of Brain Health 2026 by the European Academy of Neurology, in recognition of its research and innovation ecosystem.
Geneva has been named European Capital of Brain Health 2026, a title awarded by the European Academy of Neurology (EAN) in recognition of the city’s commitment to research, innovation and brain health awareness. Campus Biotech, the life sciences and neurotechnology hub, is among the Geneva institutions cited for the designation, alongside the HUG (Geneva University Hospitals), the University of Geneva and the CHUV.
The title was marked in late June by a program of scientific and public events, including the EAN Congress at Palexpo, one of Europe’s largest gatherings dedicated to the brain and nervous system, and public talks on the Swiss Brain Health Plan held at Campus Biotech, alongside a city-wide awareness campaign built around three messages: sleep well, stay active and eat well.
Home to research centers such as the Wyss Center for Bio and Neuro Engineering, Campus Biotech has become a focal point for neurotechnology in Western Switzerland. In December 2025, it added an AI Hub operated by the HUG with the Wyss Center and the canton’s health department, a roughly 1,000-square-meter space bringing clinicians, researchers and AI specialists together to advance diagnostics and care for conditions such as epilepsy, stroke and depression.
The campus also hosts a growing cluster of neurotech companies. Neurosoft Bioelectronics, co-founded by researchers from EPFL’s Neuro-X Institute, develops stretchable brain interface electrodes that have been tested in humans during epilepsy surgery, while BrainScape Medical develops an implantable neuromonitoring platform, licensed from the Wyss Center, that has received a U.S. FDA Breakthrough Device Designation for pharmacoresistant epilepsy.
To keep pace with demand, Campus Biotech is set to expand under Geneva’s Innovation Master Plan 2025-2027 with a new nine-story building of 3,500 square meters.
